Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.…
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Silence Therapeutics (NASDAQ: SLN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 88 employees.
The shares were at 19.81 USD on 20 November 2026, up 194.8% over 52 weeks. Its 52-week range is 4.190 USD to 19.86 USD, and it trades at the top of that range.
Its market capitalisation is 1.23B USD.
Silence Therapeutics reports return on equity of -142.2%.
It holds more cash than debt, a net cash position of 247.57M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Hold; their mean price target of 19.75 USD is 0.3% below the current price. The next earnings report is expected on 4 March 2027.